Ignite Creation Date:
2024-05-06 @ 10:05 AM
Last Modification Date:
2024-10-26 @ 12:24 PM
Study NCT ID:
NCT03162874
Status:
COMPLETED
Last Update Posted:
2020-03-17
First Post:
2017-05-19
Brief Title:
Study to Evaluate the Efficacy Safety and Tolerability of PXT002331 Foliglurax in Reducing Motor Complications of Levodopa Therapy in Parkinson Diseases Patients
Sponsor:
Prexton Therapeutics
Organization:
Prexton Therapeutics
Study Overview
Official Title:
A Multi-centre Double-blind Randomised Placebo-controlled Parallel-arm Phase IIa Trial to Evaluate the Efficacy Safety and Tolerability of 28-Day Oral Treatment With PXT002331 Foliglurax in Reducing Motor Complications of Levodopa Therapy in Subjects With Parkinsons Disease Experiencing End-of-dose Wearing Off and Levodopa-Induced Dyskinesia AMBLED
Status:
COMPLETED
Status Verified Date:
2020-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
AMBLED
Brief Summary:
This will be a double-blind randomised placebo-controlled parallel-arm phase II proof of concept in subjects with PD treated with a stable dose of levodopa who are experiencing both end-of-dose wearing off and Levodopa-Induced Dyskinesia LID
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 18023A | OTHER | Lundbeck | None |